BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mirzaei S, Mahabady MK, Zabolian A, Abbaspour A, Fallahzadeh P, Noori M, Hashemi F, Hushmandi K, Daneshi S, Kumar AP, Aref AR, Samarghandian S, Makvandi P, Khan H, Hamblin MR, Ashrafizadeh M, Zarrabi A. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems. Life Sci 2021;275:119368. [PMID: 33741417 DOI: 10.1016/j.lfs.2021.119368] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 36.0] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen PV, Hervé-aubert K, Lajoie L, Misericordia Y, Chourpa I, David S, Allard-vannier E. In vitro synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model. International Journal of Pharmaceutics: X 2022. [DOI: 10.1016/j.ijpx.2022.100139] [Reference Citation Analysis]
2 Lee Y, Kim M, Ha J, Lee M. Brain‐targeted exosome‐mimetic cell membrane nanovesicles with therapeutic oligonucleotides elicit anti‐tumor effects in glioblastoma animal models. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10426] [Reference Citation Analysis]
3 Vinh Nguyen P, Hervé-aubert K, Lajoie L, Misericordia Y, Chourpa I, David S, Allard-vannier E. WITHDRAWN: In vitro synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.122335] [Reference Citation Analysis]
4 Verdugo E, Puerto I, Medina MÁ. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun (Lond) 2022. [PMID: 36129048 DOI: 10.1002/cac2.12361] [Reference Citation Analysis]
5 Zhao J, Zhang C, Wang W, Li C, Mu X, Hu K. Current progress of nanomedicine for prostate cancer diagnosis and treatment. Biomed Pharmacother 2022;155:113714. [PMID: 36150309 DOI: 10.1016/j.biopha.2022.113714] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ashrafizadeh M, Hushmandi K, Mirzaei S, Bokaie S, Bigham A, Makvandi P, Rabiee N, Thakur VK, Kumar AP, Sharifi E, Varma RS, Aref AR, Wojnilowicz M, Zarrabi A, Karimi‐maleh H, Voelcker NH, Mostafavi E, Orive G. Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10325] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ashrafizadeh M, Aghamiri S, Tan SC, Zarrabi A, Sharifi E, Rabiee N, Kadumudi FB, Pirouz AD, Delfi M, Byrappa K, Thakur VK, Sharath Kumar KS, Girish YR, Zandsalimi F, Zare EN, Orive G, Tay F, Hushmandi K, Kumar AP, Karaman C, Karimi-maleh H, Mostafavi E, Makvandi P, Wang Y. Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology. Nano Today 2022;45:101532. [DOI: 10.1016/j.nantod.2022.101532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Duskey JT, Rinaldi A, Ottonelli I, Caraffi R, De Benedictis CA, Sauer AK, Tosi G, Vandelli MA, Ruozi B, Grabrucker AM. Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments. Pharmaceutics 2022;14:1450. [DOI: 10.3390/pharmaceutics14071450] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res 2022;41:214. [PMID: 35773731 DOI: 10.1186/s13046-022-02406-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
10 Zhao B, Wu J, Xia Y, Li H, Wang Y, Qu T, Xing H, Wang Y, Ma W. Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. Pharmacol Res 2022;182:106316. [PMID: 35724820 DOI: 10.1016/j.phrs.2022.106316] [Reference Citation Analysis]
11 Ashrafizadeh M, Zarrabi A, Karimi‐maleh H, Taheriazam A, Mirzaei S, Hashemi M, Hushmandi K, Makvandi P, Nazarzadeh Zare E, Sharifi E, Goel A, Wang L, Ren J, Nuri Ertas Y, Kumar AP, Wang Y, Rabiee N, Sethi G, Ma Z. (Nano)platforms in bladder cancer therapy: Challenges and opportunities. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 El Kheir W, Marcos B, Virgilio N, Paquette B, Faucheux N, Lauzon M. Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment. Pharmaceutics 2022;14:1189. [DOI: 10.3390/pharmaceutics14061189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Li B, Chen X, Qiu W, Zhao R, Duan J, Zhang S, Pan Z, Zhao S, Guo Q, Qi Y, Wang W, Deng L, Ni S, Sang Y, Xue H, Liu H, Li G. Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy. Adv Sci (Weinh) 2022;9:e2105451. [PMID: 35508804 DOI: 10.1002/advs.202105451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, Sethi G, Tergaonkar V. NF-κB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition. J Cell Physiol 2022. [PMID: 35561232 DOI: 10.1002/jcp.30759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
15 Du W, Zhang L, Li X, Ling G, Zhang P. Nuclear targeting Subcellular-delivery nanosystems for precise cancer treatment. International Journal of Pharmaceutics 2022;619:121735. [DOI: 10.1016/j.ijpharm.2022.121735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Mahabady MK, Mirzaei S, Saebfar H, Gholami MH, Zabolian A, Hushmandi K, Hashemi F, Tajik F, Hashemi M, Kumar AP, Aref AR, Zarrabi A, Khan H, Hamblin MR, Nuri Ertas Y, Samarghandian S. Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity. J Cell Physiol 2022;237:2309-44. [PMID: 35437787 DOI: 10.1002/jcp.30751] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Martinez Junior AM, de Souza RHFV, Petrônio MS, Martins GO, Fernandes JC, Benderdour M, Tiera VAOD, Tiera MJ. Double-grafted chitosans as siRNA nanocarriers: effects of diisopropylethylamine substitution and labile-PEG coating. J Nanostruct Chem. [DOI: 10.1007/s40097-022-00487-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Mirzaei S, Gholami MH, Hushmandi K, Hashemi F, Zabolian A, Canadas I, Zarrabi A, Nabavi N, Aref AR, Crea F, Wang Y, Ashrafizadeh M, Kumar AP. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol 2022;15:18. [PMID: 35236381 DOI: 10.1186/s13045-022-01235-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 20.0] [Reference Citation Analysis]
19 Ashrafizadeh M, Kumar A, Aref AR, Zarrabi A, Mostafavi E. Exosomes as Promising Nanostructures in Diabetes Mellitus: From Insulin Sensitivity to Ameliorating Diabetic Complications. IJN 2022;Volume 17:1229-53. [DOI: 10.2147/ijn.s350250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Xu X, Jin C, Zhang K, Cao Y, Liu J, Zhang Y, Ran H, Jin Y. Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100245] [Reference Citation Analysis]
21 Paskeh MDA, Entezari M, Clark C, Zabolian A, Ranjbar E, Farahani MV, Saleki H, Sharifzadeh SO, Far FB, Ashrafizadeh M, Samarghandian S, Khan H, Ghavami S, Zarrabi A, Łos MJ. Targeted regulation of autophagy using nanoparticles: New insight into cancer therapy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2022;1868:166326. [DOI: 10.1016/j.bbadis.2021.166326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
22 Minafra L, Cammarata FP, Calvaruso M. The Role of Radiation in Cancer Treatment: New Insights towards Personalized Therapies. JPM 2022;12:312. [DOI: 10.3390/jpm12020312] [Reference Citation Analysis]
23 Park SC, Heo H, Jang MK. Polyethylenimine grafted-chitosan based Gambogic acid copolymers for targeting cancer cells overexpressing transferrin receptors. Carbohydr Polym 2022;277:118755. [PMID: 34893210 DOI: 10.1016/j.carbpol.2021.118755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Subhan A, Attia SA, P Torchilin V. Targeted siRNA nanotherapeutics against breast and ovarian metastatic cancer: a comprehensive review of the literature. Nanomedicine (Lond) 2022;17:41-64. [PMID: 34930021 DOI: 10.2217/nnm-2021-0207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Paskeh MDA, Mehrabi A, Gholami MH, Zabolian A, Ranjbar E, Saleki H, Ranjbar A, Hashemi M, Ertas YN, Hushmandi K, Mirzaei S, Ashrafizadeh M, Zarrabi A, Samarghandian S. EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Biomed Pharmacother 2021;146:112532. [PMID: 34906772 DOI: 10.1016/j.biopha.2021.112532] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
26 Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. J Hepatocell Carcinoma 2021;8:1415-44. [PMID: 34858888 DOI: 10.2147/JHC.S336858] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
27 Mekala JR, Kurappalli RK, Ramalingam P, Moparthi NR. N-acetyl l-aspartate and Triacetin modulate tumor suppressor MicroRNA and class I and II HDAC gene expression induce apoptosis in Glioblastoma cancer cells in vitro. Life Sci 2021;286:120024. [PMID: 34626605 DOI: 10.1016/j.lfs.2021.120024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Mirzaei S, Gholami MH, Ang HL, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Delfi M, Khan H, Ashrafizadeh M, Sethi G, Kumar AP. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 2021;10:3348. [PMID: 34943856 DOI: 10.3390/cells10123348] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
29 Najafi S, Tan SC, Raee P, Rahmati Y, Asemani Y, Lee EHC, Hushmandi K, Zarrabi A, Aref AR, Ashrafizadeh M, Kumar AP, Ertas YN, Ghani S, Aghamiri S. Gene regulation by antisense transcription: A focus on neurological and cancer diseases. Biomed Pharmacother 2021;145:112265. [PMID: 34749054 DOI: 10.1016/j.biopha.2021.112265] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
30 Deldar Abad Paskeh M, Asadi S, Zabolian A, Saleki H, Khoshbakht MA, Sabet S, Naghdi MJ, Hashemi M, Hushmandi K, Ashrafizadeh M, Mirzaei S, Zarrabi A, Sethi G. Targeting Cancer Stem Cells by Dietary Agents: An Important Therapeutic Strategy against Human Malignancies. Int J Mol Sci 2021;22:11669. [PMID: 34769099 DOI: 10.3390/ijms222111669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
31 Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Zabolian A, Hashemi M, Hushmandi K, Ashrafizadeh M, Aref AR, Samarghandian S. Cervical cancer progression is regulated by SOX transcription factors: Revealing signaling networks and therapeutic strategies. Biomed Pharmacother 2021;144:112335. [PMID: 34700233 DOI: 10.1016/j.biopha.2021.112335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
32 Abadi AJ, Mirzaei S, Mahabady MK, Hashemi F, Zabolian A, Hashemi F, Raee P, Aghamiri S, Ashrafizadeh M, Aref AR, Hamblin MR, Hushmandi K, Zarrabi A, Sethi G. Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects. Phytother Res 2021. [PMID: 34697839 DOI: 10.1002/ptr.7305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 31.0] [Reference Citation Analysis]
33 Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, Zarrabi A, Goldman A, Ashrafizadeh M, Orive G. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today 2021:S1359-6446(21)00428-1. [PMID: 34624510 DOI: 10.1016/j.drudis.2021.09.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 22.0] [Reference Citation Analysis]
34 Ha J, Kim M, Lee Y, Lee M. Intranasal delivery of self-assembled nanoparticles of therapeutic peptides and antagomirs elicits anti-tumor effects in an intracranial glioblastoma model. Nanoscale 2021;13:14745-59. [PMID: 34474460 DOI: 10.1039/d1nr03455c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
35 Piperno A, Sciortino MT, Giusto E, Montesi M, Panseri S, Scala A. Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles. Int J Nanomedicine 2021;16:5981-6002. [PMID: 34511901 DOI: 10.2147/IJN.S321329] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
36 Anwar DM, El-Sayed M, Reda A, Fang JY, Khattab SN, Elzoghby AO. Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes. Expert Opin Drug Deliv 2021;:1-17. [PMID: 34254868 DOI: 10.1080/17425247.2021.1955853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
37 Mani S, Swargiary G, Tyagi S, Singh M, Jha NK, Singh KK. Nanotherapeutic approaches to target mitochondria in cancer. Life Sci 2021;281:119773. [PMID: 34192595 DOI: 10.1016/j.lfs.2021.119773] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]